Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips Sells 12,163 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the transaction, the director now owns 2 shares in the company, valued at $12.78. This represents a 99.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sera Prognostics Stock Performance

NASDAQ:SERA traded up $0.04 during mid-day trading on Tuesday, hitting $6.37. The stock had a trading volume of 134,610 shares, compared to its average volume of 143,614. Sera Prognostics, Inc. has a twelve month low of $4.98 and a twelve month high of $12.35. The stock has a market cap of $215.13 million, a price-to-earnings ratio of -6.43 and a beta of 0.86. The company’s 50 day simple moving average is $7.44 and its 200 day simple moving average is $7.31.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the company earned ($0.23) EPS. As a group, equities analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Bank of New York Mellon Corp raised its position in shares of Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares during the period. Rhumbline Advisers acquired a new position in Sera Prognostics in the 2nd quarter valued at about $190,000. American Century Companies Inc. raised its holdings in Sera Prognostics by 12.7% in the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after acquiring an additional 2,891 shares during the period. Renaissance Technologies LLC bought a new position in Sera Prognostics in the 2nd quarter valued at about $162,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Sera Prognostics during the second quarter worth approximately $68,000. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.